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Effect of Rate or Rhythm Control on
Quality of Life in Persistent Atrial Fibrillation
Results From the Rate Control Versus
Electrical Cardioversion (RACE) Study
Vincent E. Hagens, MD,* Adelita V. Ranchor, PHD,† Eric Van Sonderen, PHD,† Hans A. Bosker, MD,‡
Otto Kamp, MD,§ Jan G. P. Tijssen, PHD, J. Herre Kingma, MD,¶ Harry J. G. M. Crijns, MD,#
Isabelle C. Van Gelder, MD,* for the RACE Study Group**
Groningen, Arnhem, Amsterdam, Nieuwegein, and Maastricht, the Netherlands
OBJECTIVES We studied the influence of rate control or rhythm control in patients with persistent atrial
fibrillation (AF) on quality of life (QoL).
BACKGROUND Atrial fibrillation may cause symptoms like fatigue and dyspnea. This can impair QoL.
Treatment of AF with either rate or rhythm control may influence QoL.
METHODS Quality of life was assessed in patients included in the Rate Control Versus Electrical
Cardioversion for Persistent Atrial Fibrillation (RACE) study (rate vs. rhythm control in
persistent AF). Rate control patients (n  175) were given negative chronotropic drugs and
oral anticoagulation. Rhythm control patients (n  177) received serial electrocardioversion,
antiarrhythmic drugs, and oral anticoagulation, as needed. Quality of life was studied using
the Short Form (SF)-36 health survey questionnaire at baseline, one year, and the end of the
study (after 2 to 3 years of follow-up). At baseline, QoL was compared with that of healthy
control subjects. Patient characteristics related to QoL changes were determined.
RESULTS Mean follow-up was 2.3 years. At baseline, QoL was lower in patients than in age-matched
healthy controls. At study end, under rate control, three subscales of the SF-36 improved.
Under rhythm control, no significant changes occurred compared with baseline. At study end,
QoL was comparable between both groups. The presence of complaints of AF at baseline, a
short duration of AF, and the presence of sinus rhythm (SR) at the end of follow-up, rather
than the assigned strategy, were associated with QoL improvement.
CONCLUSIONS Quality of life is impaired in patients with AF compared with healthy controls. Treatment
strategy does not affect QoL. Patients with complaints related to AF, however, may benefit
from rhythm control if SR can be maintained. (J Am Coll Cardiol 2004;43:241–7) © 2004
by the American College of Cardiology Foundation
Atrial fibrillation (AF) causes disabling symptoms like
fatigue, dyspnea, and palpitations. Additionally, patients
may perceive their arrhythmia as life-threatening or dis-
abling. As a result, quality of life (QoL) may be drastically
reduced. Conceivably, normalizing the rhythm is beneficial
(1). Ablation of atrioventricular conduction with implanta-
tion of an artificial pacemaker was shown to improve QoL
(2–4). However, this invasive treatment is appropriate in
problematic AF only. In the usual patient, amiodarone,
sotalol, or propafenone may enhance QoL, especially if
sinus rhythm (SR) is maintained (5). At present, it is not
well known whether rhythm control is indeed superior to
rate control in terms of QoL. The Pharmacological Inter-
vention in Atrial Fibrillation (PIAF) trial investigators
demonstrated that the type of treatment (either rhythm
control using cardioversion and antiarrhythmic drug treat-
ment or rate control, aiming at an adequate ventricular rate
during accepted AF) did not affect QoL (6). Follow-up was
limited to one year, and rhythm control did not include
serial cardioversions and serial antiarrhythmic drug treat-
ment. In this study, the Rate Control Versus Electrical
Cardioversion for Persistent Atrial Fibrillation (RACE)
study, we analyzed QoL in patients randomized to rate or
rhythm control (1). The aim of this study was to determine:
1) QoL in patients with persistent AF, as compared with
that in age-matched healthy control subjects; 2) changes
over time, and to compare rhythm and rate control with
respect to these changes; and 3) to determine predictors
(i.e., clinical characteristics) of improvement or a decrease in
QoL.
METHODS
Patient population. This study was performed in patients
with persistent AF included in the RACE study (1). The
study was approved by the institutional review boards of
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each participating hospital, and all patients gave written,
informed consent. In the RACE study, we included 522
patients with recurrent persistent AF who were randomized
to rate or rhythm control. It was shown that both strategies
were associated with a comparable rate of cardiovascular
adverse events. For the present analysis, we included all 352
patients who completed the self-administered QoL ques-
tionnaire at baseline, after one year, and at the end of
follow-up (end of study: at 24 months for 134 patients and
at 36 months for 218 patients). Patients who died during
the follow-up of RACE were not analyzed (18 patients in
the rate control and 18 patients in the rhythm control
group). Another 134 patients (63 rate and 71 rhythm
control patients) did not complete the QoL questionnaire at
either baseline, one year, or the end of the study and were
excluded. All the excluded patients did not differ signifi-
cantly from included patients at baseline and follow-up.
Patient characteristics at baseline are shown in Table 1.
Quality-of-life questionnaire. Quality of life was assessed
using the Medical Outcomes Study Short-Form 36 (SF-36)
health survey questionnaire (7). The SF-36 is a standard-
ized, validated, generic health survey that has been fre-
quently used in arrhythmia studies. The SF-36 has been
translated and validated in the Netherlands (8). It contains
items to assess physical health (e.g., general health percep-
Abbreviations and Acronyms
AF  atrial fibrillation
AFFIRM  Atrial Fibrillation Follow-up Investigation
of Rhythm Management trial
CTAF  Canadian Trial of Atrial Fibrillation trial
HF  heart failure
NYHA  New York Heart Association
PIAF  Pharmacological Intervention in Atrial
Fibrillation trial
QoL  quality of life
RACE  Rate Control Versus Electrical
Cardioversion for Persistent Atrial
Fibrillation trial
SF-36  Short-Form 36
SR  sinus rhythm





Age (yrs) 68  9 68  8
Male gender 107 (61%) 119 (67%)
Total AF duration (days) 511 (14–14,909) 495 (1–8,513)
Duration present episode of AF (days) 33 (1–392) 36 (1–376)
Complaints of AF 129 (74%) 124 (70%)
Fatigue 75 (58%) 67 (54%)
Dyspnea 67 (52%) 59 (48%)
Palpitations 50 (39%) 43 (35%)
Heart rate at inclusion (beats/min) 91  20 90  20
Underlying diseases (%)
Coronary artery disease 22 28
Old myocardial infarction 12 17
Valvular disease 19 13
Mitral valve disease 14 11
Aortic disease 5 3
Aortic and mitral valve disease 0 1
Cardiomyopathy 11 6
History of hypertension 42 53
History of chronic obstructive lung disease 21 15
Diabetes mellitus 11 10
No heart disease 22 21




Previous ischemic thromboembolic complication 17 12
Stroke 5 4
Previous hemorrhagic complication 9 7
Echocardiographic parameters
Left ventricular end-diastolic diameter (mm) 53  7 52  7
Left ventricular end-systolic diameter (mm) 37  8 37  8
Fractional shortening (%) 31  9 30  10
Left atrial diameter, parasternal long axis (mm) 45  7 45  7
Left atrial diameter, apical view (mm) 64  8 63  8
Right atrial diameter, parasternal long axis (mm) 58  8 57  8
Data are presented as the mean value  SD, number (%) of subjects, median value (range), or percentage of subjects.
AF  atrial fibrillation; NYHA  New York Heart Association.
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tion, physical functioning, role limitations due to physical
problems and bodily pain) and mental health (social func-
tioning, role limitations due to emotional problems, mental
health, and vitality). The SF-36 scale, which measures
change in health, is not considered in the analyses. The
items for general health perception and vitality measure
both. Each scale is composed of a number of multiple-
choice questions, ranging in a stepwise fashion from im-
paired/low QoL to not impaired/high QoL. For each of the
eight subscales, scores are transformed to a scale ranging
from 0 to 100, with lower scores representing a lower QoL.
Complaints related to AF were assessed at each study
visit, using a standardized questionnaire attached to the case
record form. Complaints at inclusion were assessed for the
current episode of AF before randomization.
Statistical analysis. At baseline, all patients were compared
with a healthy, age-matched control group consisting of 172
Dutch subjects who served to validate the Dutch version of
the SF-36. At baseline, at one year, and at the end of the
study, the scores on all subscales of the SF-36 were
compared between the rate and rhythm control groups.
To analyze patient characteristics associated with low
QoL at baseline, patients with low scores (scores lower than
the mean value  1 SD) were identified. To assess the
relevance of changes in the different subscales over time,
changes in the scores from baseline to the end of the study
were divided into relevant and irrelevant. For each of the
eight subscales, the relevance of a change in QoL was
defined according to the number of steps by which the
patient improved or worsened on the multiple-choice ques-
tions that comprised each SF-36 subscale. The following
changes in QoL for the individual patient were regarded as
relevant and relied on the number of questions that com-
prised each SF-36 subscale: 1 step for role limitations due to
physical problems and for role limitations due to emotional
problems; 2 steps for social functioning and bodily pain; and
3 steps for general health perception, physical functioning,
mental health, and vitality. The effect sizes were calculated
according to Cohen (9) by dividing the differences in the
mean QoL score by the pooled standard deviation to assess
the change in QoL for each subscale within the randomized
arm. Clinical correlates of a change in QoL, including
clinical baseline and follow-up characteristics, were deter-
mined. Subanalysis was performed to determine whether
relevant QoL changes were correlated with randomized
strategy. To examine changes over time for each SF-36
scale, the method of repeated measures was performed. For
a comparison of scores between groups and with the control
group, the Student t test for independent variables was used.
The univariate chi-square test and Student t test for
independent variables, followed by multivariate stepwise
regression analyses, were performed to determine indicators
of relevant QoL changes over follow-up. All analyses were
performed on an intention-to-treat basis.
RESULTS
QoL at baseline. Quality of life at baseline did not differ
between the 352 analyzed patients and the patients for
whom the baseline questionnaire was available but who had
to be excluded for missing follow-up questionnaires. Also,
their baseline characteristics were comparable (data not
shown). At baseline, there were no significant differences in
QoL between the rate and rhythm control groups (Table 2).
At study entry, QoL was lower for our patients compared
with a healthy, age-matched control group. Differences in
physical and emotional role limitations were highest
(Fig. 1).
Low QoL scores for physical health at baseline (scores on
the subscales under the mean value  1 SD) were more
frequent among: 1) females (p  0.01; physical functioning
and physical role limitations); 2) patients whose age was
under the median value of 69 years (p  0.05; physical
functioning); 3) patients with a duration of AF above the
median of 32 days (p  0.05; physical functioning); and 4)
patients with reduced exercise tolerance (New York Heart
Association [NYHA] functional class II/III) (p  0.05;
general health, physical functioning, role physical, and
bodily pain). Low QoL scores for mental health were more
frequent among patients 69 years old (p  0.05; mental
health and social functioning). Patients with complaints of
AF, especially fatigue (p  0.05; general health, physical
functioning, physical role limitations, bodily pain, social
functioning, and vitality), and those with reduced fractional
shortening (p  0.05; role physical, social functioning, and
vitality) had a reduced score for both physical and mental
health parameters.
Quality of life from baseline to study end. At 12-month
follow-up in the rate control group, four subscales of the
SF-36 had improved (Table 2). At study end, three sub-
scales had significantly improved: role limitations due to
physical problems, social functioning, and mental health.
Physical functioning worsened over time.
After one year of rhythm control therapy, QoL improved
on three subscales, including two scales measuring physical
health. However, at the end of the study, no significant
changes were present compared with baseline scores.
When the scores on the SF-36 subscales at 12-month
follow-up and study end were compared between the rate
and rhythm control groups, no significant differences were
found in any of the eight subscales (Table 2). The absolute
differences between the scores at baseline and study end
were not statistically different between rate and rhythm
control. The percentage of patients with a relevant increase
in follow-up was generally higher than that of patients with
a relevant decrease in QoL over time; however, the effect
sizes within each randomized strategy were small and always
below 0.25 (i.e., one-fourth of SD) (Table 2).
The occurrence of complaints related to AF was compa-
rable between the rate and rhythm control groups over
follow-up. Fatigue and dyspnea were most common.
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Determinants of QoL changes. For the total study group,
we investigated which baseline (Table 1) and follow-up
parameters were related to a relevant change in each
subscale of the SF-36 at study end. The follow-up para-
meters were randomized strategy, underlying disease,
NYHA class for heart failure (HF), improvement or wors-
ening of echocardiographic parameters (left ventricular and
atrial diameters, fractional shortening), presence of SR at
study end, and occurrence of a severe adverse cardiovascular
event, including HF, thromboembolic complication, bleed-
ing, implantation of a pacemaker, or severe adverse effects of
medication.
Stepwise regression analyses revealed that age 69 years,
complaints of AF (especially fatigue and dyspnea) at inclu-
sion, a short duration of AF, and SR at the end of follow-up
were determinants of relevant QoL improvement during
follow-up (Table 3; only determinants that were significant
with use of multivariate analysis are shown). The type of
randomized strategy (rate or rhythm control) was not
associated with relevant changes.
A total of 35 patients (10%) showed a major improve-
ment in QoL, defined as relevant improvements on five or
more subscales of the SF-36. Characteristics (baseline and
follow-up parameters) associated with improved QoL on
five or more subscales were the same as those identified
using the stepwise regression analysis: younger age (69
years, p  0.020), shorter duration of AF (32 days, p 
0.005), presence of dyspnea (p  0.048) or fatigue (p 
0.005) at inclusion, and SR at the end of the study (p 
0.003). In 23 patients (6.5%), QoL on five or more subscales
deteriorated. No parameters were related to a significant
decrease in QoL on five or more subscales.
For the rate control group alone, the presence of SR at
study end resulted in a relevant improvement in QoL on five
or more subscales (p  0.002). However, the number of
patients who improved was small (5 of 17 patients with SR
at study end in the rate control group). For the rhythm
control group, younger age (p  0.041), shorter duration of
AF (p  0.026), and presence of SR at end of the study led
to a relevant QoL improvement (11 of 65 patients with SR
at study end, p  0.022). The number of electrical cardio-
versions needed in these patients with SR at study end did
not have any association with QoL.
There were no interactions between the determinants of
QoL and the randomized strategy, indicating that there
were no subgroups of patients in whom either rate or
rhythm control is preferable.
DISCUSSION
This study shows that patients with persistent AF have a
lower QoL than their healthy age-matched controls. Fur-
thermore, QoL did not change significantly during long-
term rhythm control treatment, whereas during rate control
treatment, minor changes occurred. However, there were no
differences in QoL between the rate control and rhythm
Table 2. Short-Form 36 Quality-of-Life Scores
SF-36 Subscale

















Rate 54 (19) 58 (18)* 57 (18) 3 0.16 23 14
Rhythm 54 (18) 58 (20)* 54 (20) 0 0 19 16
Physical functioning
Rate 62 (24) 62 (23) 59 (25)*† 3 0.12 14 22
Rhythm 64 (24) 67 (24)* 64 (27) 0 0 18 21
Role physical
Rate 45 (46) 59 (42)* 53 (44)* 8 0.18 26 18
Rhythm 50 (44) 61 (43)* 55 (45) 5 0.11 23 17
Bodily pain
Rate 80 (22) 81 (21) 79 (23) 1 0.04 14 20
Rhythm 81 (21) 82 (22) 80 (22) 1 0.05 16 15
Mental health
Rate 73 (18) 77 (18)* 76 (17)* 3 0.17 25 14
Rhythm 74 (18) 76 (19) 76 (18) 2 0.11 25 18
Social functioning
Rate 76 (24) 81 (21)* 81 (21)* 5 0.22 26 13
Rhythm 78 (22) 79 (25) 80 (23) 2 0.09 16 11
Role emotional
Rate 73 (41) 76 (38) 73 (39) 0 0 19 18
Rhythm 70 (42) 74 (39) 74 (38) 4 0.10 24 17
Vitality
Rate 60 (22) 59 (20) 59 (21) 1 0.05 16 19
Rhythm 60 (21) 62 (21) 62 (21) 2 0.10 25 17
*p  0.05 compared with baseline score. †p  0.05 compared with 12-month score. ‡No significant differences between groups.
SF-36  Medical Outcomes Study Short-Form 36.
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control groups at the end of follow-up. Finally, maintenance
of SR rather than the assigned treatment strategy was an
important parameter for improvement of QoL.
QoL in persistent AF. Compared with healthy volunteers,
QoL was significantly reduced in our patients. This is in
accordance with Dorian et al. (10), who showed that
patients with heart disease (either AF or HF or ischemic
heart disease) had lower scores on the SF-36 subscales than
did healthy controls. However, this is in contrast to another
study in which a cohort of older ambulatory patients with
chronic AF (mean age 76 years) was compared with an
age-matched control group of patients in SR. In the latter
study, exercise tolerance and QoL were comparable between
both groups, even though a higher level of comorbidity was
found in the AF group (11).
In the present study, impaired QoL at baseline predom-
inantly occurred in patients with complaints related to AF
(especially fatigue), patients with more severe underlying
heart disease (NYHA class II/III HF and/or reduced
fractional shortening), and females. About 80% of our
patients had, apart from AF, underlying heart disease,
which may have contributed significantly to their com-
plaints and impaired QoL (10,12,13). Complaints were an
important determinant of reduced physical and mental
Figure 1. Quality-of-life comparison between study patients at baseline and control subjects.*p  0.05. Solid bars  RACE subjects (n  352); open bars
 control subjects (n  172).





Coefficient (95% CI) p Value
Relevant Improvement
Physical functioning Sinus rhythm at study end 0.15 (0.04 to 0.27) 0.007
Role physical Sinus rhythm at study end 0.12 (0.00 to 0.24) 0.047
Complaints of AF at baseline 0.12 (0.01 to 0.24) 0.041
Bodily pain Duration of present AF 32 days* 0.13 (0.24 to 0.02) 0.024
Social functioning Duration of present AF 32 days* 0.12 (0.23 to 0.10) 0.032
Age 69 years* 0.18 (0.29 to 0.07) 0.001
Vitality Sinus rhythm at study end 0.23 (0.11 to 0.33)  0.001
Relevant Decrease
Role emotional Coronary artery disease at baseline 0.20 (0.32 to 0.08) 0.001
Vitality Diabetes at baseline 0.14 (0.26 to 0.03) 0.011
*Median value. No significance was reached on multivariate analysis in the subscales of general health and mental health.
AF  atrial fibrillation; CI  confidence interval; QoL  quality of life; SF-36  Medical Outcomes Study Short-Form 36.
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health scores of QoL. It may be speculated that these
complaints were (predominantly) caused by the presence of
underlying heart disease, and not by AF, especially since
fatigue and dyspnea, and not palpitations, were the most
frequent complaints in patients with reduced QoL. How-
ever, complaints such as fatigue are also a common finding
in patients with AF without underlying heart disease (14).
Why females had an impaired QoL is difficult to explain.
However, in the Canadian Trial of Atrial Fibrillation
(CTAF), QoL was also significantly impaired in women
compared with men, despite comparable severity of under-
lying heart disease (15).
Rate versus rhythm control. At the end of the study, no
differences between the rate and rhythm control groups were
present. For the rate control group, improvements in phys-
ical and mental scales of the SF-36 were present at 12-
month follow-up and at the end of the study. Because
almost all patients had persistent AF, and no spontaneous
improvements might be expected given the age of the
patients, these may be regarded as a general treatment effect
of both the arrhythmia and underlying disease. The latter
includes adjustments of rate control therapy and therapy for
the underlying heart disease, as needed, and careful and
close monitoring by the treating physician and study nurses.
At study end, physical functioning was significantly re-
duced. This is likely related to an impaired physical capacity
as a consequence of progression of chronic underlying heart
disease and noncardiac illness in this elderly study popula-
tion. After 12-month of follow-up, QoL in patients treated
according to the rhythm control protocol improved on three
SF-36 subscales but returned to baseline scores at study end.
This also may relate to the aforementioned issues, but also
to the fact that after 12 months, 55% of patients were still
in SR (vs. 39% at study end).
These trends in both groups indicate that treatment of
AF in a study like this, with relatively frequent visits, may
improve QoL in the short term, possibly due to treatment
effects, irrespective of the kind of therapy. However, during
long-term follow-up, these improvements largely vanish.
No significant changes in QoL could be demonstrated
between the two treatment groups. This may relate to the
fact that SR could be maintained only in a minority of
patients during long-term follow-up.
The CTAF, PIAF, and Atrial Fibrillation Follow-up
Investigation of Rhythm Management (AFFIRM) investi-
gators recently performed comparable QoL assessments
with follow-up studies at one year (5,6,16). In AFFIRM, no
significant differences between the two groups at any point
during follow-up could be demonstrated (16). The PIAF
investigators showed a significant improvement in QoL at
12-month follow-up for almost all SF-36 subscales in both
the rate and rhythm control groups. In contrast, our study
showed only a few changes after 12-month follow-up. The
CTAF study, which randomized patients after successful
cardioversion to amiodarone, sotalol, or propafenone,
showed that after three months of rhythm control therapy,
QoL improved independent of the drug used, compared
with baseline QoL. At 12-month follow-up, QoL remained
unchanged.
Predictors of changes of QoL. As in CTAF, we also
found that SR at the end of the study was the most
important determinant of QoL improvement. In CTAF
and in the present study, improvements were present for
both physical and mental health scales, indicating that SR
may improve exercise tolerance and a sense of vitality. Thus,
rhythm control may be beneficial in improving QoL if
effective. Therefore, better means of maintaining SR may
have a major general impact on QoL in patients with
persistent AF.
In the present study, 10% of the patients showed a major
QoL improvement, defined as a relevant increase on five or
more SF-36 subscales. Improvements may be expected in
younger patients, patients with a short duration of AF, and
subjects in whom SR was restored. In general, if SR can be
restored and maintained during long-term follow-up, an
improvement of QoL can be expected. Therefore, these
patients remain candidates for the rhythm control strategy,
notwithstanding the results of PIAF, AFFIRM, and RACE
(1,6,16).
Study limitations. It is important to state that QoL covers
a wide range of patients’ sense of well-being, complaints in
daily living, complaints of cardiac and noncardiac diseases,
and social functioning. Although the SF-36 is a validated
questionnaire for QoL research, it is possible that some
aspects of QoL or changes in QoL in patients with AF are
not measured. In further research, additional QoL measure-
ments, using, for example, AF-specific questionnaires, as
previously used by Dorian et al. (5,10), are warranted.
Conclusions. Patients with persistent AF have a lower
QoL than do healthy, age-matched controls. This holds
true especially for patients with complaints of AF, those
with symptoms of HF, and females. Treatment strategy
(rate or rhythm control) does not greatly influence QoL, as
only minor changes occurred on the SF-36 scores. This
predominantly relates to the fact that more than half of the
patients in the rhythm control strategy had permanent AF
during the last period of follow-up. Improvement of QoL is
most likely to occur in patients in whom SR can be
maintained during long-term follow-up.
Although rate control is not inferior to rhythm control,
with regard to morbidity and mortality (AFFIRM and
RACE), long-term SR by a rhythm control approach may
be preferable for improvement of subjective general
well-being.
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